[Treatment of hypertension with a drug combination, consisting of bemetizide, triamterene, dihydralazine and bupranolol (author's transl)].
The optimal daily dose and dose regimen of a new drug combination (Pertenso), consisting of 10 mg bemetizide, 20 mg triamterene, 20 mg dihydralazine and 20 mg bupranolol were tested in 14 hypertensive outpatients (WHO I to III) in a single blind crossover trial. The mean blood pressure before treatment was 183/107 +/- 5/2 mm Hg (+/-SEM) and was lowered to a mean blood pressure of 147/89 +/- 4/4 mm Hg (+/- SEM; p less than 0,005) during a multiple dose regimen and to 141/84 +/- 3/3 mm Hg (+/- SEM; p less than 0,005) during a single dose regimen. The results indicate that even in hypertension which requires a combination of diuretics, vasodilators and beta-adrenergic blocking agents for treatment, a fixed combination of these substances could be given for effective blood pressure control. The data suggest the possibility of a single dose regimen of the fixed drug combination.
D000328:Adult; D001581:Benzothiadiazines / Q000627:therapeutic use*; D002046:Bupranolol / Q000627:therapeutic use*; D004078:Dihydralazine / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D006830:Hydralazine / Q000031:analogs & derivatives*; D006973:Hypertension / Q000188:drug therapy*; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*; D011674:Pulse / Q000187:drug effects; D014223:Triamterene / Q000627:therapeutic use*
D001581:Benzothiadiazines; D004338:Drug Combinations; D011412:Propanolamines; D006830:Hydralazine; D002046:Bupranolol; C010100:dehydrosanol; D004078:Dihydralazine; D014223:Triamterene
Hypertoniebehandlung mit einem Kombinationspräparat, bestehend aus Bemetizid, Triamteren, Dihydralazin und Bupranolol.